Hasanov Lab Code to Clinic

PUBLICATIONS

Selected publications and conference abstracts from the Hasanov Lab, highlighting work in machine learning, artificial intelligence, cancer genomics, translational oncology, tumor immunology, biomarker discovery, and clinical outcomes research.

2026

  1. Majeed Z, Ozgul S, Li P, Suki D, Acikgoz Y, Jonasch E, Ferguson SD, Hasanov M, Hasanov E. Explainable ML/AI model for estimating postoperative survival in renal cell carcinoma brain metastasis patients. Neuro-Oncology Advances. Published May 28, 2026.
  2. Ali MI, Akpinar ZF, Ovando-Ricardez JA, Casasent AK, Lam TNA, Lin J, Khanmammadova N, Reville PK, Shih DJ, Osunkoya AO, Norberg LM, Tran TM, Hanalioglu S, Bilen MA, Lang FF, Huse JT, Navin N, Hasanov M, Jonasch E, Hasanov E. Single-cell atlas of renal cell carcinoma brain metastasis uncovers mechanisms of immune dysfunction and resistance. bioRxiv. Posted May 10, 2026. doi:10.64898/2026.05.06.722652.
  3. Gok Yavuz B, Li P, Ovando-Ricardez JA, La Ferlita A, Tse JWT, Hanalioglu S, Babaoglu B, Baylarov B, Norberg LM, Chancoco H, Thompson EJ, Mut M, Soylemezoglu F, Huse JT, Osunkoya AO, Bilen MA, Hasanov M, Jonasch E, Shih DJ, Hasanov E. Deciphering the genomic landscape of renal cell carcinoma brain metastases. bioRxiv. Posted May 6, 2026. doi:10.64898/2026.05.02.722447.
  4. Li P, Majeed Z, Ozgul S, Ali MI, Single N, Stover DG, Makary MS, Bicer F, Mortazavi A, Rathmell WK, Singer EA, Niazi K, Wu RC, Hasanov M, Hasanov E. Machine learning–based transcriptomic signatures to predict treatment outcomes across targeted and immunotherapy regimens in renal cell carcinoma. J Clin Oncol. 2026;44(suppl 16):4526. doi:10.1200/JCO. 2026.44.16_suppl.4526
  5. Deshmukh S, Ali MI, Ovando-Ricardez JA, Lam TN, Hoang A, Liu X, Wang X, Peterson CB, Xiao L, Matin SF, Sircar K, Tannir NM, Hasanov M, Jonasch E, Hasanov E. Spatial transcriptomic profiling of the tumor microenvironment associated with sunitinib response in metastatic renal cell carcinoma. J Clin Oncol. 2026;44(suppl 16):3119. doi:10.1200/JCO. 2026.44.16_suppl.3119
  6. Gok Yavuz B, Li P, Ovando-Ricardez JA, La Ferlita A, Tse JW, Hanalioglu S, Babaoglu B, Baylarov B, Norberg LM, Chancoco H, Thompson E, Mut M, Soylemezoglu F, Huse JT, Osunkoya AO, Bilen MA, Hasanov M, Jonasch E, Shih DJ, Hasanov E. Deciphering the genomic landscape of renal cell carcinoma brain metastases. J Clin Oncol. 2026;44(suppl 16):4524. doi:10.1200/JCO.2026.44.16_suppl.4524
  7. Hasanov E, Majeed Z, Faieta A, Gok Yavuz B, Folefac E, Monk P III, Shabsigh A, Clinton SK, Mortazavi A, Singer EA, Hasanov M. Real-world overall survival outcomes of belzutifan treatment in advanced renal cell carcinoma. J Clin Oncol. 2026;44(suppl 16):4561. doi:10.1200/JCO.2026.44.16_suppl.4561
  8. Faieta A, Majeed Z, Mammadzada N, Bicer F, Folefac E, Monk P III, Singer EA, Shabsigh A, Mortazavi A, Hasanov M, Clinton SK, Hasanov E. Real-world overall survival outcomes of lutetium Lu 177 vipivotide tetraxetan treatment in prostate cancer. J Clin Oncol. 2026;44(suppl 16):5033. doi:10.1200/JCO.2026.44.16_suppl.5033
  9. Qin Q, Zhang S, Tachibana I, Lin L, Hasanov E, Singer EA, Geynisman DM, Kutikov A, Zibelman MR, Reimers MA, Maldonado J, VanderWeele DJ, Kundu S, Paul AK, Melson JW, Gaston K, Margulis V, Cadeddu JA, Zhang T. A phase II trial of neoadjuvant zanzalintinib plus nivolumab in patients with locally advanced and/or surgically challenging clear cell renal cell carcinoma: EXPLORE-RCC. J Clin Oncol. 2026;44(suppl 16):TPS4629. doi:10.1200/JCO.2026.44.16_suppl. TPS4629
  10. Das A, Balkhi SS, Mitta LA, Qadar A, Vesely S, Gunter T, Cookson M, Stratton KL, McIntosh AG, Patel S, Cross B, Yang YA, Hasanov E, Bupathi M, Garmezy B, McKay RR, Raza J, Ayanambakkam A. Phase II study of cemiplimab ± fianlimab following SBRT for oligometastatic clear-cell RCC: LAG-BOOST. J Clin Oncol. 2026;44(suppl 16):TPS4637. doi:10.1200 /JCO.2026.44.16_suppl.TPS4637
  11. Ali MI, Akpinar Z, Ovando-Ricardez JA, Casasent AK, Lam TN, Lin J, Khanmammadova N, Reville PK, Shih DJ, Osunkoya AO, Norberg LM, Tran TM, Hanalioglu S, Bilen MA, Lang FF, Huse JT, Navin N, Hasanov M, Jonasch E, Hasanov E. Single-cell characterization of renal cell carcinoma brain metastasis. J Clin Oncol. 2026;44(suppl 16):e14013. doi:10.1200/JCO.2026.44.16_suppl.e14013
  12. Ali MI, Majeed Z, Li P, Verschraegen CF, Niazi K, Hasanov E, Hasanov M. An optimized machine learning model for overall survival prediction in brain metastasis patients using genomic mutation and copy number features. J Clin Oncol. 2026;44(suppl 16):e14002. doi:10.1200/JCO.2026.44.16_suppl.e14002
  13. Faieta A, Majeed Z, Wu RC, Kendra KL, Hasanov M, Hasanov E, Verschraegen CF. Real-world overall survival after PD-1 failure in advanced cutaneous squamous cell carcinoma. J Clin Oncol. 2026;44(suppl 16):e21570. doi:10.1200/JCO. 2026.44.16_suppl.e21570
  14. Majeed Z, Li P, Verschraegen CF, Hays JL, Niazi K, Hasanov M, Hasanov E. In silico phase III clinical trial of avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma using a machine learning model transfer approach. J Clin Oncol. 2026;44(suppl 16):e16500. doi:10.1200/JCO.2026.44.16_suppl.e16500
  15. Faieta A, Majeed Z, Folefac E, Monk P III, Shabsigh A, Clinton SK, Singer EA, Mortazavi A, Hasanov M, Hasanov E. Real-world survival outcomes and prognostic factors with adjuvant pembrolizumab for renal cell carcinoma. J Clin Oncol. 2026;44(suppl 16):e16555. doi:10.1200/JCO.2026.44.16_suppl.e16555
  16. Majeed Z, Faieta A, Acikgoz Y, Folefac E, Monk P III, Shabsigh A, Clinton SK, Mortazavi A, Singer EA, Hasanov M, Hasanov E. Real-world toxicity outcomes with adjuvant pembrolizumab following nephrectomy for renal cell carcinoma. J Clin Oncol. 2026;44(suppl 16):e23447. doi:10.1200/JCO.2026.44.16_suppl.e23447
  17. Abu Alragheb B, Ozgul S, Ali MI, Acikgoz Y, Abu Alragheb R, Li P, Majeed Z, Cevik L, Niazi K, Wu RC, Hasanov M, Hasanov E. Decoding cancers of unknown primary through genomics-driven clustering: a pan-cancer framework for prognostic classification using AACR GENIE data. J Clin Oncol. 2026;44(suppl 16):e15006. doi:10.1200/JCO.2026.44.16_suppl.e15006
  18. Li M, Mortazavi A, Backes FJ, Zimmerman DE, Wu RC, Meng L, Presley CJ, Konda B, Mittra A, Hasanov M, Hasanov E, Liebner DA, Alahmadi A, Patel DC, Wei L, Meara AS, Owen DH, Li Z, Verschraegen CF, Yang YA. Siltuximab for the prevention of severe immune-related adverse events during immune checkpoint inhibitor rechallenge in advanced cancer: first interim analysis of the CIRES trial. J Clin Oncol. 2026;44(suppl 16):e24146. doi:10.1200/JCO.2026.44.16_suppl. e24146
  19. Yu K, Chen J, Chu YY, Nair S, Crupi E, Hasanov E, Mei Y, Han X, Liu Y, Liu Y, Pei G, Peng F, Liao J, Dai E, Chu T, Cho KS, Jiang J, Yan X, Dai Y, Wang J, Zhang B, Genovese G, Putluri N, Eberlin L, Yang L, Lin C, Kwong LN, Shamsutdinova D, Wani KM, Czerniak BA, Yu W, Zhao J, Guo CC, Hansel D, Pettaway C, Pisters L, Bree K, Navai N, Lee BH, Kamat AM, Sharma P, Corn P, Jiang CY, Shah AY, Alhalabi O, Msaouel P, Siefker-Radtke AO, Logothetis CJ, Campbell MT, Lazar AJ, Gao J, Wang L. A spatial atlas of muscle-invasive bladder cancer reveals lineage-specific vulnerabilities and immune architecture. Cancer Discov. Published online May 13, 2026. doi:10.1158/2159-8290.CD-26-0099
  20. Chen Y, Su Z, Niazi MK, Parwani AV, Hasanov E. Integrating image and text-based AI improves identification of metastatic sites from whole-slide pathology images. Cancer Res. 2026;86(7 suppl):2771. doi:10.1158/1538-7445. AM2026-2771
  21. Meng L, Yang YA, Chowdhury SM, Hong EF, Khorasanchi A, Mortazavi A, Singer EA, Wang SJ, Gauntner TD, Coller KA, Wang P, Zimmerman DE, Bicer F, Folefac E, Hasanov E, Monk P III, Clinton SK, Feuer H, et al. Circulating tumor DNA dynamics as a predictive biomarker of response and survival in metastatic urothelial carcinoma treated with enfortumab vedotin and pembrolizumab. J Clin Oncol. 2026;44(7 suppl):860. doi:10.1200/JCO.2026.44.7_suppl.860
  22. Chen Y, Su Z, Meng L, Hasanov E, Chen W, Parwani A, Niazi MKK. HistoMet: a pan-cancer deep learning framework for prognostic prediction of metastatic progression and site tropism from primary tumor histopathology. arXiv. Preprint posted online February 7, 2026. Revised May 5, 2026. arXiv:2602.07608.
  23. Akbar AR, Leyva A, Esnakula A, Hasanov E, Noonan A, Manne U, Sahai V, Meng L, Tsai S, Parwani A, Chen W, Manne A, Niazi MKK. Inferring clinically relevant molecular subtypes of pancreatic cancer from routine histopathology using deep learning. medRxiv. Preprint posted online January 8, 2026. doi:10.1101/2026.01.06.26345339

2025

  1. Gok Yavuz B, Khanmammadova N, Majeed Z, Ali MI, Hasanov M, Bilen MA, Singer EA, Hasanov E. Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics. Trends Cancer. 2026;12 (2):186-207. Published online December 2, 2025. doi:10.1016/j.trecan.2025.11.001
  2. LaPelusa M, Chamseddine S, Cao HST, Xiao L, Hasanov E, Bhosale P, Amin HM, Mohamed YI, Gok Yavuz B, Sakr Y, Xu L, Hu I, Lee SS, Sakamuri D, Jindal S, Nguyen V, Curran MA, Sun R, Rashid A, Duda DG, Sharma P, Qayyum A, Kaseb AO. Tissue and imaging biomarkers of response to neoadjuvant nivolumab or nivolumab plus ipilimumab in patients with resectable hepatocellular carcinoma. Oncology. 2025;103(6):490-497. Published online October 18, 2024. doi:10.1159/000541250
  3. Hasanov E, Fynt L, Tidwell RS, Hwong H, Brooks R, Wood LM, Solley T, Syed M, Venkatesan AM, Jonasch E. STARLITE 1: phase 1b/2 study of combined ^177Lu-girentuximab plus cabozantinib and nivolumab in treatment-naïve patients with advanced clear-cell renal cell carcinoma. Eur Urol Focus. 2025;11(3):401-403. doi:10.1016/j.euf.2025.04.003
  4. Akula V, Chen L, Acikgoz Y, Klein K, Gok Yavuz B, Cevik L, Demir T, Manne A, Sahin I, Kaseb A, Hasanov E. Neoadjuvant immune checkpoint inhibitors for hepatocellular carcinoma. NPJ Precis Oncol. 2025;9(1):60. Published online March 6, 2025. doi:10.1038/s41698-025-00846-4
  5. Moussa MJ, Khandelwal J, Wilson NR, Malikavil KL, Surasi DS, Bathala TK, Lin Y, Rao P, Tamboli P, Sircar K, Ajufo H, Elsayes KM, Shah A, Johns AC, Goswami S, Hasanov E, Jonasch E, Msaouel P, Campbell MT, Alhalabi O, Tannir NM. Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology non-clear cell renal cell carcinoma. J Immunother Cancer. 2025;13(2):e010958. Published online February 12, 2025. doi:10.1136/jitc-2024-010958
  6. Meng L, Collier KA, Hasanov E, Mortazavi A, Clinton SK, Wang P, Zimmerman DE, Bicer FB, Gauntner TD, Folefac E, Monk P III, Yang Y. Concordance of circulating tumor DNA and imaging surveillance in patients with urothelial carcinoma and renal cell carcinoma post-immunotherapy. Presented at: ASCO Abstracts & Presentations.
  7. Moussa MJ, Khandelwal J, Wilson NR, Malikavil KL, Surasi DS, Bathala TK, Lin Y, Rao P, Tamboli P, Sircar K, Ajufo H, Elsayes KM, Shah A, Johns AC, Goswami S, Hasanov E, Jonasch E, Msaouel P, Campbell MT, Alhalabi O, Tannir NM. Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology non-clear cell renal cell carcinoma. J Immunother Cancer. 2025;13(2):e010958. doi:10.1136/jitc-2024-010958
  8. Kamau K, Byrne L, Sund D, Sood A, Wang SJ, Yang Y, Meng L, Wang P, Zimmerman DE, Hasanov E, Bicer F, Gauntner TD, Folefac E, Monk P III, Clinton SK, Mortazavi A, Collier KA. Germline genetic variants in cancers of the urothelial tract and association with outcomes. J Clin Oncol. 2025;43(5 suppl):870. doi:10.1200/JCO.2025.43.5_suppl.870

2024

  1. Sood A, Singer EA, Hasanov E, Davis JW. From the Editor September 2024: The spectrum of clinical trial reports. JU Open Plus. 2024;2(10):e00112. doi:10.1097/JU9.0000000000000229
  2. Hasanov M, Martin B, Hasanov E, Wu RCH, Goldberg MS, Cook RW, Kendra KL, Jarell A. The 31-GEP to identify patients with localized cutaneous melanoma at the highest risk of metastasis to the central nervous system. J Clin Oncol. 2024;42(16 suppl):9530. doi:10.1200/JCO.2024.42.16_suppl.9530
  3. Kamau K, Byrne L, Sundi D, Wang SJ, Yang YA, Meng L, Wang P, Zimmerman DE, Hasanov E, Folefac E, Monk P III, Clinton SK, Mortazavi A, Collier KA. Germline genetic variants in cancers of the bladder, renal pelvis, ureter, or urethra. J Clin Oncol. 2024;42(16 suppl):e16626. doi:10.1200/JCO.2024.42.16_suppl.e16626
  4. Goodstein T, Goldberg I, Acikgoz Y, Hasanov E, Srinivasar R, Singer EA. Special populations in metastatic renal cell carcinoma. Curr Opin Oncol. 2024;36(3):186-194. Published online February 23, 2024. doi:10.1097/CCO. 0000000000001028
  5. Wilson NR, Acikgoz Y, Hasanov E. Advances in non-clear cell renal cell carcinoma management: from heterogeneous biology to treatment options. Int J Cancer. 2024;154(6):947-961. Published online October 12, 2023. doi:10.1002/ijc. 34756
  6. Hasanov E, Hammers HJ, George DJ, Rini BI, Beckermann K, Palmer JD, Mortazavi A, Brooks R, Solley T, Wood LM, Haas NB, McDermott DF, Vaishampayan UN, Jonasch E. A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade. J Clin Oncol. 2024;42(4 suppl):TPS497. doi:10.1200/JCO.2024.42.4_suppl.TPS497
  7. LaPelusa MB, Chamseddine S, Xiao L, Hasanov E, Bhosale P, Abugabal YI, Gok Yavuz B, Yadav SS, Cao HST, Xu L, Hu ZI, Lee SS, Sakamuri D, Curran MA, Jindal S, Duda GD, Sharma P, Qayyum A, Kaseb AO. Serologic, radiographic, and tissue-based markers associated with major pathologic response after treatment with neoadjuvant immunotherapy in patients with resectable hepatocellular carcinoma. J Clin Oncol. 2024;42(3 suppl):561. doi:10.1200/JCO.2024.42.3_suppl. 561

2023

  1. Liu XD, Zhang YT, McGrail DJ, Zhang X, Lam T, Hoang A, Hasanov E, Manyam G, Peterson CB, Zhu H, Kumar SV, Akbani R, Pilie PG, Tannir NM, Peng G, Jonasch E. SETD2 loss and ATR inhibition synergize to promote cGAS signaling and immunotherapy response in renal cell carcinoma. Clin Cancer Res. 2023;29(19):4002-4015. doi:10.1158/1078-0432. CCR-23-1003
  2. Hasanov E, Jonasch E. Management of brain metastases in metastatic renal cell carcinoma. Hematol Oncol Clin North Am. 2023;37(5):1005-1014. Published online June 1, 2023. doi:10.1016/j.hoc.2023.04.020
  3. Alhalabi O, Thouvenin J, Négrier S, Vano YA, Campedel L, Hasanov E, Bakouny Z, Hahn AW, Bilen MA, Msaouel P, Choueiri TK, Viswanathan SR, Sircar K, Albiges L, Malouf GG, Tannir NM. Immune checkpoint therapy combinations in adult advanced MiT family translocation renal cell carcinomas. Oncologist. 2023;28(5):433-439. doi:10.1093 /oncolo/oyac262
  4. Hasanov E, Lam TNA, Lin J, Reville PK, Hasanov M, Casasent AK, Shih D, Hanalioglu S, Bilen MA, Alhalabi O, Babaoglu B, Baylarov B, Osunkoya AO, Norberg LM, Gumin J, Tran TM, Li J, Hoang AG, Chancoco HD, Parker Kerrigan BC, Thompson EJ, Kim BYS, Suki D, Mut M, Soylemezoglu F, Genovese G, Akdemir KC, Tawbi HA, Tannir NM, McAllister F, Davies MA, Sharma P, Huse J, Lang F, Navin N, Jonasch E. Single-cell and spatial transcriptomic mapping of human renal cell carcinoma brain metastases uncovers actionable immune-resistance targets. Cancer Res. 2023;83(7 suppl): 5788. doi:10.1158/1538-7445.AM2023-5788

Before 2023

  1. Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Bilen MA, Choueiri TK, Albiges L, Tannir NM, Malouf GG. Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas. Oncologist. 2022;7(12):1041-1047. doi:10.1093/oncolo/oyac158
  2. Hasanov E, Yeboa DN, Tucker MD, Swanson TA, Beckham TH, Rini BI, Ene CI, Hasanov M, Derks S, Smith NR, Daniali S, Hend MD, Brastianos PK, Bex A, Hanalioglu S, Weinberg JS, Hirsch L, Carlo MI, Aizer A, Brown PD, Bilen MA, Chang EL, Jaboin J, Brugarolas J, Choueiri TK, Atkins MB, McGregor BA, Halasz LM, Patel TR, Soltys SG, McDermott DF, Elder JB, Baskaya MK, Yu JB, Timmerman R, Kim MM, Mut M, Markert J, Beal K, Tannir NM, Samandouras G, Lang FF, Giles R, Jonasch E. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin. 2022;72(5):454-489. Published online June 16, 2022. doi:10.3322/caac.21729
  3. Hasanov E, Herrera Caceres JO, Maskens DA, Giles RH, Schmidt AM. Patient-reported outcomes: what really matters to patients?. Lancet Oncol. 2022;23(5):e198. doi:10.1016/S1470-2045(22)00165-4
  4. Hasanov E, Pimentel I, Cruellas M, Lewis MA, Jonasch E, Balmaña J. Current systemic treatments for the hereditary cancer syndromes: drug development in light of genomic defects. Am Soc Clin Oncol Educ Book. 2022;42:808-824. doi: 10.1200/EDBK_350232
  5. Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Gok Yavuz B, Mohamed YI, Qayyum A, Jindal S, Duan F, Basu S, Yadav SS, Nicholas C, Sun JJ, Raghav KPS, Rashid A, Carter K, Chun YS, Tzeng CWD, Sakamuri D, Xu L, Sun R, Cristini V, Beretta L, Yao JC, Wolff RA, Allison JP, Sharma P. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):208-218. doi:10.1016/S2468-1253(21)00427-1
  6. Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y. Serum IGF-1 scores and clinical outcomes in the phase III IMbrave150 study of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:1065-1079. doi:10.2147/JHC.S369951
  7. Wilson NR, Alhalabi O, Hasanov E, Xiao L, Papadopoulos J, Campbell MT, Shah A, Gao J, Corn PG, Aparicio A, Wang J, Czerniak BA, Guo CC, Logothetis CJ, Li J, Choi S, Tang C, Tannir NM, Siefker-Radtke AO. Immune checkpoint blockade in brain metastases from advanced small cell urothelial cancer. J Immunother Cancer. 2021;9(suppl 2):A259-A260. doi: 10.1136/jitc-2021-SITC2021.241
  8. Gok Yavuz B, Hasanov E, Xiao L, Mohamed YI, Lee S, Rashid A, Kaseb A, Qayyum A. The role of tissue stiffness in predicting the immunotherapy response in hepatocellular carcinoma. J Immunother Cancer. 2021;9(suppl 2):A49. doi: 10.1136/jitc-2021-SITC2021.042
  9. Gok Yavuz B, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, Cristini V, Kaseb AO. Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1195-1207. Published online September 24, 2021. doi:10.2147/JHC.S322289
  10. Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang L, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer. 2021;149(2):387-393. Published online March 19, 2021. doi:10.1002/ijc.33560
  11. Hasanov E, Jonasch E. MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma. Expert Opin Investig Drugs. 2021;30(5):495-504. Published online May 20, 2021. doi:10.1080/13543784. 2021.1925248
  12. Alhalabi O, Soomro Z, Sun R, Hasanov E, Albittar A, Tripathy D, Valero V, Ibrahim NK. Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. NPJ Breast Cancer. 2021;7(1):28. Published online March 19, 2021. doi:10.1038/s41523-021-00235-7
  13. Hasanov E, Gao J, Tannir NM. The immunotherapy revolution in kidney cancer treatment: scientific rationale and first-generation results. Cancer J. 2020;26(5):419-431. doi:10.1097/PPO.0000000000000471
  14. Hasanov E, Tabayoyong W, Chen J, Yang G, Nie F, Meng J, Hoang A, Zhu Y, Efstathiou E, Bondaruk J, Wang WL, Guo CC, Zhang M, Czerniak B, Logothetis C, Kamat AM, Gao J. Analysis of chemotherapy-related modulation of the immune microenvironment in muscle invasive bladder cancer. J Clin Oncol. 2020;38(15 suppl):5049. doi:10.1200/JCO.2020.38.15_suppl.5049
  15. Jonasch E, Hasanov E, Motzer RJ, Hariharan SL, Choueiri TK, Huang B, Haanen JBA, Albiges L, Venugopal B, Schmidinger M, Larkin JMG, Grimm MO, Negrier S, Wang J, Mariani M, Chudnovsky A, Di Pietro A, Rini BI. Evaluation of brain metastasis in JAVELIN Renal 101: efficacy of avelumab plus axitinib versus sunitinib. J Clin Oncol. 2020;38(6 suppl):687. doi:10.1200/JCO.2020.38.6_suppl.687
  16. Hasanov E, Tidwell RSS, Fernandez P, Park L, McMichael C, Tannir NM, Jonasch E. Phase II study of carfilzomib in patients with refractory renal cell carcinoma. Clin Genitourin Cancer. 2019;17(6):451-456. doi:10.1016/j.clgc.2019.07.003
  17. Hasanov E, Peterson CB, Matin SF, Wood CG, Sircar K, Tannir NM, Jonasch E. Hypoxia signaling and immune infiltration in a presurgical trial of sunitinib in patients with clear cell renal cell carcinoma. J Clin Oncol. 2019;37(15 suppl):e16115. doi:10.1200/JCO.2019.37.15_suppl.e16115
  18. Hasanov E, Fard EV, Puravath A, Johnston JS, Peerbhai S, Rojas-Hernandez CM. T-cell large granular lymphocytic leukaemia in the context of rheumatoid arthritis. Lancet. 2018;392(10152):1071. doi:10.1016/S0140-6736(18)32208-6
  19. Jonasch E, Slack RS, Geynisman DM, Hasanov E, Milowsky MI, Rathmell WK, Stovall S, Juarez D, Gilchrist TR, Pruitt L, Ornstein MC, Plimack ER, Tannir NM, Rini BI. Phase II study of two weeks on, one week off sunitinib scheduling in patients with metastatic renal cell carcinoma. J Clin Oncol. 2018;36(16):1588-1593. doi:10.1200/JCO.2017.77.1485
  20. Pilié PG, Hasanov E, Matin SF, Henriksen Woodson AH, Marcott VD, Bird S, Slack RS, Fuller GN, McCutcheon IE, Jonasch E. Pilot study of dovitinib in patients with von Hippel-Lindau disease. Oncotarget. 2018;9:2390-2395. doi: 10.18632/oncotarget.25171
  21. Hasanov E, Chen G, Chowdhury P, Weldon J, Ding Z, Jonasch E, Sen S, Walker CL, Dere R. Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL. Oncogene. 2017;36(24):3450-3463. Published online January 23, 2017. doi:10.1038/onc.2016.495
  22. Jonasch E, Hasanov E, Corn PG, Moss T, Shaw R, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano F, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol. 2017;28(4):804-808. doi:10.1093/annonc/mdw676